CD33 and acute myeloid leukemia: CD33 is expressed on the majority of AML cells, and the experience of using gemtuzumab, an anti-CD33 antibody drug conjugate, in the treatment of pediatric AML provides hope that anti-CD33 CAR-T cells will be effective.28